Quest Diagnostics Hits New 52-Week High of $189.23, Reflecting Strong Performance

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 189.23 on September 26, 2025. This achievement underscores the company's robust performance in the market, particularly as it has demonstrated a remarkable 33.59% increase over the past year, significantly outpacing the S&P 500's performance of 15.64%.
As a mid-cap company with a market capitalization of USD 29,720 million, Quest Diagnostics operates within the miscellaneous industry. The stock's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation relative to earnings. Additionally, the company boasts a notable dividend yield of 87.16%, which may appeal to income-focused investors.

Financially, Quest Diagnostics maintains a debt-to-equity ratio of 0.76, indicating a balanced approach to leveraging, while its return on equity is reported at 14.78%. The price-to-book ratio of 4.11 further illustrates the company's valuation in relation to its assets. Overall, this new high marks a significant point in Quest Diagnostics' performance trajectory.